Chronic kidney disease and vascular dementia


Cite item

Full Text

Abstract

The paper shows the value of chronic kidney disease as a population-wide determinant of vascular dementia, including moderate cognitive impairments. It discusses the role of risk factors of cardiovascular events, including those associated with chronic kidney disease, in the development of vascular dementia and moderate cognitive impairments.

Full Text

Хроническая болезнь почек и сосудистая деменция. - Аннотация. Представлено значение хронической болезни почек как общепопуляционной детерминанты сосудистой деменции, в том числе умеренных когнитивных расстройств. Обсуждается роль факторов риска развития сердечно-сосудистых осложнений, в том числе связанных с хронической болезнью почек, в развитии сосудистой деменции и умеренных когнитивных расстройств.
×

References

  1. Кутырина И.А. Ремоделирование сосудов при хронической почечной недостаточности. В кн.: Нефрология. Национальное руководство. Под ред. Н.А. Мухина. М: ГЭОТАР-Медиа 2009: 608-616.
  2. Helmer C., Stengel B., Metzger M. et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011; 77 (23): 2043-2051.
  3. Etgen T., Chonchol M., Förstl H., Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 2012; 35 (5): 474-482.
  4. Vogels S.C., Emmelot-Vonk M.H., Verhaar H.J., Koek H.D. The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review. Maturitas 2012; 71 (4): 331-336.
  5. Raphael K.L., Wei G., Greene T., Baird B.C., Beddhu S. Cognitive function and the risk of death in chronic kidney disease. Am J Nephrol 2012; 35 (1): 49-57.
  6. Clozer M., Kuhn H., Hefti F., Baumgartner H.R. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 1991; 18 (2): 132-141.
  7. Tamura MKurella., Mapes D.L., Port F.K., Chertow G.M. Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2006; 21: 2543-2548.
  8. Pereira A.A., Weiner, D.E., Scott T., Sarnak M.J. Cognitive function in dialysis patients. Am J Kidney Dis 2005; 45: 448-462.
  9. Hailpern S.M., Melamed M.L., Cohen, H.W., Hostetter T.H. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2007; 18: 2205-2213.
  10. Рогова И.В., Фомин В.В., Дамулин И.В., Шашкова Е.В. Особенности когнитивной дисфункции у больных хронической болезнью почек на додиализных стадиях. Тер арх 2013; 6: 35-40.
  11. Штульман Д.Р., Левин О.С. Умеренные когнитивные нарушения. Неврология. Справочник практического врача. М: Медпресс-информ 2005; 226-229.
  12. Янсен В., Брукнер Г.В. Лечение хронической цереброваскулярной недостаточности с использованием драже актовегин форте (двойное слепое плацебо-контролируемое исследование). РМЖ 2002; 12-13: 543-546.
  13. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington: American Psychiatry Association. 1994.
  14. Левин О.С., Голубева Л.В. Гетерогенность умеренного когнитивного расстройства: диагностические и терапевтические аспекты. Консилиум 2006; 12: 106-110.
  15. Yaffe K., Ackerson L., Kurella Tamura M. et al. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc 2010; 58 (2): 338-345.
  16. Khatri M., Nickolas T., Moon Y.P., Paik M.C. CKD Associates with Cognitive Decline. J Am Soc Nephrol 2009; 20 (11): 2427-2432.
  17. Kurella M., Yaffe K., Shlipak M.G. et al. Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 2005; 45: 66-76.
  18. Elias M.F., Elias P.K., Seliger S.L. et al. Chronic kidney disease, creatinine and cognitive functioning. Nephrol Dial Transplant 2009; 24: 2446-2452.
  19. Barzilay J.I., Fitzpatrick A.L., Luchsinger J. et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis 2008; 52 (2): 216-226.
  20. Kurella Tamura M., Muntner P., Wadley V. et al. Albuminuria, Kidney Function, and the Incidence of Cognitive Impairment Among Adults in the United States. Am J Kidney Dis 2011 Originally published online.
  21. Kaindl A.M., Sifringer M., Koppelstaetter A. et al. Erythropoietin protects the developing brain from hyperoxia-induced cell death and proteome changes. Ann Neurol 2008; 64: 523-534.
  22. Дамулин И.В. Патогенетические, диагностические и терапевтические аспекты сосудистых когнитивных нарушений. Consilium Medicum 2006; 8: 80-85.
  23. Cottone S., Mulè G., Guarneril M. et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 2008; 24: 497-503.
  24. Praticò D., Clark C.M., Liun F. et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59 (6): 972-976.
  25. Sastre M., Calero M., Pawlik M. et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004; 25: 1033-1043.
  26. Yaffe K., Lindquist K., Shlipak M.G. et al. Cystatin-C as a Marker of Cognitive Function in Elders: Findings from the Health ABC Study. Ann Neurol 2008; 63 (6): 798-802.
  27. Mahoney C.A., Arieff A.I. Central and peripheral nervous system effects of chronic renal failure. Kidney Int 1983; 24: 170-177.
  28. Agganis B.T., Weiner D.E., Giang L.M. et al. Depression and Cognitive Function in Maintenance Hemodialysis Patients. Am J Kidney Dis 2010; 56 (4): 704-712.
  29. Батюшин М.М., Постникова Е.С., Терентьев В.П., Деревянкина И.В. Коррекция цереброренальных взаимоотношений при артериальной гипертензии, осложненной ишемическим инсультом: эффективность фиксированной комбинации эпросартана мезилата и гидрохлортиазида. Клин нефрол 2009; 1: 59-61.
  30. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033-1041.
  31. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
  32. Dahlof B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  33. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.
  34. Fourth Joint Task Force Of The European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414.
  35. Feng L., Bee Yap K., Pin Ng T. Depressive symptoms in older adults with chronic kidney disease: mortality, quality of life outcomes, and correlates. Am J Geriatr Psychiatry 2013; 21 (6): 570-579.
  36. Jain N., Trivedi M.H., Rush A.J. et al. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemp Clin Trials 2012; 34 (1): 136-144.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies